Published Paper Details:

Hypertension is a major complication often associated with diabetes mellitus, significantly increasing the risk of cardiomyopathy, stroke, hyperlipidemia, ischemic cerebrovascular disease, and peripheral vascular disease. These complications contribute substantially to morbidity and mortality, especially among middle-aged and older individuals. Metoprolol tartrate, a beta-blocker, is widely used for the management of hypertension and prevention of cardiac complications in diabetic patients. The objective of this research was to develop a sustained-release (SR) formulation of metoprolol tartrate for once-daily administration to improve therapeutic efficacy and patient compliance. Sustained-release tablet formulations (F1 to F7) were prepared using release-retarding agents such as HPMC K100 and Eudragit RSPO. The granules for the SR tablets were evaluated for their flow properties to ensure uniformity and reproducibility during the manufacturing process. The formulated SR tablets were subjected to various evaluations, including weight variation, hardness, thickness, swelling index, and in vitro drug release studies. The optimized formulation (F7) demonstrated a controlled and sustained drug release for 12 hours, ensuring a consistent therapeutic effect. The results indicate that the developed sustained-release formulation of metoprolol tartrate offers an effective once-daily treatment option for hypertension. This novel formulation has the potential to enhance patient compliance, improve treatment outcomes, and significantly contribute to the management of hypertension and associated cardiovascular risks.